{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:48:36Z","timestamp":1791895716751,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40257-021-00650-3","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T09:02:41Z","timestamp":1634806961000},"page":"93-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug"],"prefix":"10.1007","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct03170388","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Linda","family":"Stein Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon H.","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Callender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Sadick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil A.","family":"Tanghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"issue":"1","key":"650_CR1","first-page":"15","volume":"85","author":"JQ Del Rosso","year":"2010","unstructured":"Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis. 2010;85(1):15\u201324.","journal-title":"Cutis"},{"issue":"5","key":"650_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u201373.e33.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"650_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4065\/mcp.2010.0575","volume":"86","author":"MT Brown","year":"2011","unstructured":"Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304\u201314.","journal-title":"Mayo Clin Proc"},{"key":"650_CR4","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2147\/PPA.S117437","volume":"10","author":"S Moradi Tuchayi","year":"2016","unstructured":"Moradi Tuchayi S, Alexander TM, Nadkarni A, Feldman SR. Interventions to increase adherence to acne treatment. Patient Prefer Adherence. 2016;10:2091\u20136.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"650_CR5","first-page":"103","volume":"86","author":"BA Yentzer","year":"2010","unstructured":"Yentzer BA, Ade RA, Fountain JM, Clark AR, Taylor SL, Fleischer AB Jr, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010;86(2):103\u20138.","journal-title":"Cutis"},{"issue":"11","key":"650_CR6","first-page":"30","volume":"4","author":"LH Kircik","year":"2011","unstructured":"Kircik LH. Synergy and its clinical relevance in topical acne therapy. J Clin Aesthet Dermatol. 2011;4(11):30\u20133.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"4","key":"650_CR7","first-page":"s148","volume":"18","author":"LH Kircik","year":"2019","unstructured":"Kircik LH, Draelos ZD, Berson DS. Polymeric emulsion technology applied to tretinoin. J Drugs Dermatol. 2019;18(4):s148\u201354.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"650_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-021-00594-8","volume":"22","author":"H Baldwin","year":"2021","unstructured":"Baldwin H, Webster G, Stein Gold L, Callender V, Cook-Bolden FE, Guenin E. 50 years of topical retinoids for acne: evolution of treatment. Am J Clin Dermatol. 2021;22(3):315\u201327.","journal-title":"Am J Clin Dermatol"},{"issue":"2 Pt 3","key":"650_CR9","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0190-9622(98)70440-2","volume":"39","author":"B Shroot","year":"1998","unstructured":"Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol. 1998;39(2 Pt 3):S17-24.","journal-title":"J Am Acad Dermatol"},{"key":"650_CR10","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=016921. Accessed 9 Jul 2021."},{"issue":"1","key":"650_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/120347540100500109","volume":"5","author":"JJ Leyden","year":"2001","unstructured":"Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF. The efficacy and safety of a combination benzoyl peroxide\/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide\/erythromycin combination product. J Cutan Med Surg. 2001;5(1):37\u201342.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"650_CR12","first-page":"165","volume":"67","author":"EH Tschen","year":"2001","unstructured":"Tschen EH, Katz HI, Jones TM, Monroe EW, Kraus SJ, Connolly MA, et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis. 2001;67(2):165\u20139.","journal-title":"Cutis"},{"issue":"2","key":"650_CR13","first-page":"110","volume":"84","author":"LS Gold","year":"2009","unstructured":"Gold LS, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84(2):110\u20136.","journal-title":"Cutis"},{"issue":"3","key":"650_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/bjd.20080","volume":"185","author":"B Stuart","year":"2021","unstructured":"Stuart B, Maund E, Wilcox C, Sridharan K, Sivaramakrishnan G, Regas C, et al. Topical preparations for the treatment of mild-to-moderate acne vulgaris: systematic review and network meta-analysis. Br J Dermatol. 2021;185(3):512\u201325.","journal-title":"Br J Dermatol"},{"issue":"2","key":"650_CR15","first-page":"160","volume":"5","author":"JQ Del Rosso","year":"2006","unstructured":"Del Rosso JQ, Tanghetti E. The clinical impact of vehicle technology using a patented formulation of benzoyl peroxide 5%\/clindamycin 1% gel: comparative assessments of skin tolerability and evaluation of combination use with a topical retinoid. J Drugs Dermatol. 2006;5(2):160\u20134.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"650_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1046\/j.1365-2230.2001.00839.x","volume":"26","author":"AR Martin","year":"2001","unstructured":"Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne: assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001;26(5):380\u20135.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"650_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s13555-017-0185-2","volume":"7","author":"J Leyden","year":"2017","unstructured":"Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293\u2013304.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6 Pt 2","key":"650_CR18","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/S0190-9622(97)70050-1","volume":"36","author":"B Shroot","year":"1997","unstructured":"Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997;36(6 Pt 2):S96\u2013103.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"650_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/1203475415591117","volume":"19","author":"L Culp","year":"2015","unstructured":"Culp L, Moradi Tuchayi S, Alinia H, Feldman SR. Tolerability of topical retinoids: are there clinically meaningful differences among topical retinoids? J Cutan Med Surg. 2015;19(6):530\u20138.","journal-title":"J Cutan Med Surg"},{"issue":"10","key":"650_CR20","first-page":"5","volume":"15","author":"M Dutil","year":"2010","unstructured":"Dutil M. Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Lett. 2010;15(10):5\u20137.","journal-title":"Skin Therapy Lett"},{"key":"650_CR21","first-page":"549","volume":"8","author":"TA Nguyen","year":"2015","unstructured":"Nguyen TA, Eichenfield LF. Profile of clindamycin phosphate 1.2%\/benzoyl peroxide 3.75% aqueous gel for the treatment of acne vulgaris. Clin Cosmet Investig Dermatol. 2015;8:549\u201354.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"650_CR22","doi-asserted-by":"publisher","first-page":"14658","DOI":"10.1038\/s41598-019-50746-4","volume":"9","author":"MAT Blaskovich","year":"2019","unstructured":"Blaskovich MAT, Elliott AG, Kavanagh AM, Ramu S, Cooper MA. In vitro antimicrobial activity of acne drugs against skin-associated bacteria. Sci Rep. 2019;9(1):14658.","journal-title":"Sci Rep"},{"issue":"6","key":"650_CR23","first-page":"417","volume":"82","author":"JJ Leyden","year":"2008","unstructured":"Leyden JJ, Wortzman M, Baldwin EK. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis. 2008;82(6):417\u201321.","journal-title":"Cutis"},{"issue":"2","key":"650_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00128071-200405020-00002","volume":"5","author":"HH Tan","year":"2004","unstructured":"Tan HH. Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. Am J Clin Dermatol. 2004;5(2):79\u201384.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"650_CR25","first-page":"256","volume":"5","author":"E Tanghetti","year":"2006","unstructured":"Tanghetti E, Abramovits W, Solomon B, Loven K, Shalita A. Tazarotene versus tazarotene plus clindamycin\/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. J Drugs Dermatol. 2006;5(3):256\u201361.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"650_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaad.2007.06.006","volume":"57","author":"DM Thiboutot","year":"2007","unstructured":"Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57(5):791\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"650_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40257-016-0178-4","volume":"17","author":"L Stein Gold","year":"2016","unstructured":"Stein Gold L, Weiss J, Rueda MJ, Liu H, Tanghetti E. Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3%\/benzoyl peroxide 2.5% gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17(3):293\u2013303.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"650_CR28","first-page":"1083","volume":"13","author":"DM Pariser","year":"2014","unstructured":"Pariser DM, Rich P, Cook-Bolden FE, Korotzer A. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2014;13(9):1083\u20139.","journal-title":"J Drugs Dermatol"},{"key":"650_CR29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jaad.2008.06.040","volume":"59","author":"D Thiboutot","year":"2008","unstructured":"Thiboutot D, Zaenglein AL, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59:792\u2013800.","journal-title":"J Am Acad Dermatol"},{"key":"650_CR30","unstructured":"US Food and Drug Administration. Medical review addendum for BenzaClin. 2000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/50-756_Benzaclin_medr.pdf. Accessed 6 Jul 2021."},{"key":"650_CR31","unstructured":"Duac\u00ae [package insert]. Stiefel Laboratories, Inc., Research Triangle Park, NC; December 2013."},{"key":"650_CR32","unstructured":"Clindamycin Gel [package insert]. Clindagel, LLC., Santa Rosa, CA; November 2000."},{"issue":"7","key":"650_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1346-8138.2010.01109.x","volume":"38","author":"M Song","year":"2011","unstructured":"Song M, Seo SH, Ko HC, Oh CK, Kwon KS, Chang CL, et al. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea. J Dermatol. 2011;38(7):667\u201373.","journal-title":"J Dermatol"},{"key":"650_CR34","unstructured":"Amzeeq\u00ae [package insert]. VYNE Pharmaceuticals, Inc., Bridgewater, NJ; January 2021."},{"issue":"1","key":"650_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/jdv.16686","volume":"35","author":"AS Karadag","year":"2021","unstructured":"Karadag AS, Aslan Kay\u0131ran M, Wu CY, Chen W, Parish LC. Antibiotic resistance in acne: changes, consequences and concerns. J Eur Acad Dermatol Venereol. 2021;35(1):73\u20138.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00650-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:56:45Z","timestamp":1642744605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00650-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00650-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"12 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Ortho Dermatologics. Medical writing support for this article was also funded by Ortho Dermatologics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Linda Stein Gold has served as an investigator\/consultant or speaker for Ortho Dermatologics, LEO Pharma, Dermavant, Incyte, Novartis, AbbVie, Pfizer, Sun Pharma, UCB, Arcutis, and Lilly. Hilary Baldwin has served as an advisor or investigator and on speakers\u2019 bureaus for Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma. Leon H. Kircik has acted as an investigator, advisor, speaker, and consultant for Ortho Dermatologics. Jonathan S. Weiss is a consultant, speaker, advisor, and\/or researcher for AbbVie, Ortho Dermatologics, Janssen Biotech, Dermira, Almirall, Brickell Biotech, DermTech, and Scynexis. David M. Pariser has served as a consultant to Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, Celgene, Dermira, LEO Pharma, Regeneron, Sanofi, TDM SurgiTech, TheraVida, and Ortho Dermatologics; an investigator for Abbott Laboratories, Almirall, Amgen, AOBiome, Asana Biosciences, Bickel Biotechnology, Celgene, Dermavant, Dermira, Eli Lilly, LEO Pharma, Menlo Therapeutics, Merck & Co., Novartis, Novo Nordisk A\/S, Ortho Dermatologics, Pfizer, Regeneron, and Stiefel; on the advisory board for Pfizer; and on the data monitoring board for BMS. Valerie Callender has served as an investigator, consultant, or speaker for AbbVie, Galderma, L\u2019Or\u00e9al, Ortho Dermatologics, and Vyne. Edward Lain has nothing to disclose. Michael Gold has acted as an investigator, advisor, speaker, and consultant for Ortho Dermatologics. Kenneth Beer has received funding from Allergan, Galderma, Evolus, and Revance. Zoe Draelos received research funding from Ortho Dermatologics. Neil Sadick has served on advisory boards, as a consultant, investigator, speaker, and\/or other and has received honoraria and\/or grants\/research funding from Almirall, Actavis, Allergan, Anacor Pharmaceuticals, Auxilium Pharmaceuticals, Bausch Health, Bayer, Biorasi, BTG, Carma Laboratories, Cassiopea, Celgene Corporation, Cutera, Cynosure, DUSA Pharmaceuticals, Eclipse Medical, Eli Lilly and Company, Endo International, EndyMed Medical, Ferndale Laboratories, Galderma, Gerson Lehrman Group, Hydropeptide, Merz Aesthetics, Neostrata, Novartis, Nutraceutical Wellness, Palomar Medical Technologies, Prescriber\u2019s Choice, Regeneron, Roche Laboratories, Samumed, Solta Medical, Storz Medical AG, Suneva Medical, Vanda Pharmaceuticals, and Venus Concept. Radhakrishnan Pillai and Varsha Bhatt are employees of Bausch Health US, LLC and may hold stock and\/or stock options in its parent company. Emil A. Tanghetti has served as a speaker for Novartis, Ortho Dermatologics, Sun Pharma, Lilly, Galderma, AbbVie, and Dermira; served as a consultant in clinical studies for Hologic, Ortho Dermatologics, and Galderma; and is a stockholder for Accure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was carried out in accordance with principles of Good Clinical Practice and the Declaration of Helsinki. At all investigational sites, the study protocol was approved by the relevant independent ethics committees or institutional review boards. All participants or their legal guardians provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants or their legal guardians provided written informed consent before entering the clinical trial from which the data were derived.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Additional informed consent was obtained from all individual participants for whom identifying information\/photographs are included in this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to the conception or design of the work; drafted the work\/revised it critically; approved the version to be published; and agree to be accountable for all aspects of this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}